3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
57
Nivolumab
50
Ipilimumab
31
Specimen Handling
23
Magnetic Resonance Spectroscopy
19
Cyclophosphamide
14
Biopsy
11
fludarabine
10
binimetinib
10
Opdualag
10
trametinib
9
relatlimab
9
Radiosurgery
9
CTLA-4 Antigen
9
dabrafenib
8
lifileucel
7
fludarabine phosphate
7
aldesleukin
7
encorafenib
6
Interleukin-2
6
cemiplimab
5
atezolizumab
5
Paclitaxel
5
Blood Specimen Collection
5
X-Rays
4
Taxes
4
Pemetrexed
4
Gemcitabine
4
Cisplatin
4
Carboplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Genetic Counseling
×
90 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled